Blood Disorder Therapeutics Market - Trends, Share, Growth & Size

Name: Blood Disorder Therapeutics Market - Trends, Share, Growth & Size
Creator: Mordor Intelligence
License: https://www.mordorintelligence.com/privacy-policy

Blood Disorder Therapeutics Market Size and Share

Market Overview

Study Period	2019 - 2030
Base Year For Estimation	2024
Forecast Data Period	2025 - 2030
Historical Data Period	2019 - 2023
Growth Rate	6.20% CAGR
Fastest Growing Market	Asia Pacific
Largest Market	North America
Major Players *Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

bleeding disorders therapeutics market size — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Blood Disorder Therapeutics Market Analysis by Mordor Intelligence

The Blood Disorder Therapeutics Market is expected to register a CAGR of 6.2% during the forecast period.

Global Blood Disorder Therapeutics Market Trends and Insights

Recombinant Factors Segment is Expected to Hold a Significant Market Share in the Blood Disorder Therapeutics Market

Worldwide, the rising prevalence of blood disorders and increasing adoption of recombinant factor concentrates are the key drivers of the recombinant factors segment.
A recombinant factor is a form of blood factor that is manufactured via recombinant technology. Recombinant factors are used in the treatment of disorders such as hemophilia (prevention and control of hemorrhagic episodes).
According to the World Federation of Hemophilia Report, in the year 2017, worldwide around 315,423 people are affected by bleeding disorders. Among them approximately 196,706 people are living with Hemophilia, 76,144 people with von Willebrand disease (VWD) and 42,573 with other bleeding disorders. Furthermore, according to the National Hemophilia Foundation, approximately 75% of people with hemophilia around the world still do not receive adequate treatment or have no access to treatment.
Recombinant factors segment hold a significant market share by revenue and is anticipated to show steady growth over the forecast period due to the growing need to treat blood-related disorders and increase in production of recombinant products globally.

bleeding disorders therapeutics market trends — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the blood disorder therapeutics market due to rising prevalence of various blood disorders and increasing awareness among the patient population in this region. According to the World Federation of Hemophilia, in the United States alone there are around 18 thousand people with hemophilia and over 11 thousand with von Willebrand disease. In addition, Hemophilia A affects 1 in 5,000 male births and approximately 400 babies are born with hemophilia A each year. Furthermore, increasing investments in research and development to develop treatment options for blood disorders and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

bleeding disorders therapeutics market analysis — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The Blood Disorder Therapeutics Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi, Novo Nordisk A/S, CSL Ltd, Pfizer Inc, Bayer AG, Celgene Corporation, Alexion Pharmaceuticals, Inc, Amgen Inc and AstraZeneca Plc.

Blood Disorder Therapeutics Industry Leaders

Takeda Pharmaceutical Company Limited (Shire Plc)
Sanofi
Novo Nordisk A/S
CSL Ltd
Pfizer Inc
*Disclaimer: Major Players sorted in no particular order

Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi, Novo Nordisk A/S, CSL Ltd, Pfizer Inc, Bayer AG, Celgene Corporation, Alexion Pharmaceuticals, Inc — Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Need More Details on Market Players and Competitors?

Download PDF

Table of Contents for Blood Disorder Therapeutics Industry Report

1. INTRODUCTION

1.1 Study Assumptions
1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Various Blood Disorders
- 4.2.2 Increasing Investment in R&D for Advance Treatment Options
4.3 Market Restraints
- 4.3.1 High Cost of Treatment
- 4.3.2 Stringent Regulations Norms
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

5.1 By Product Type
- 5.1.1 Plasma Derived Factors
- 5.1.2 Recombinant Factors
- 5.1.3 Other Products
5.2 By Application
- 5.2.1 Hemoglobin Diosrders
- 5.2.2 Platelet Based Disorders
- 5.2.3 Plasma Disorders
- 5.2.4 Myeloproliferative Disorders
- 5.2.5 Genetic Hematology Disorders
- 5.2.6 Blood Cancers
- 5.2.7 Other Application
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

6.1 Company Profiles
- 6.1.1 Takeda Pharmaceutical Company Limited (Shire Plc)
- 6.1.2 Sanofi
- 6.1.3 Novo Nordisk A/S
- 6.1.4 CSL Ltd
- 6.1.5 Pfizer Inc
- 6.1.6 Bayer AG
- 6.1.7 Celgene Corporation
- 6.1.8 Alexion Pharmaceuticals, Inc
- 6.1.9 Amgen Inc
- 6.1.10 AstraZeneca Plc
*List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections

Get Price Break-up Now

Global Blood Disorder Therapeutics Market Report Scope

Blood disorders are conditions that impact the blood's ability to function correctly. Most blood disorders decrease the number of platelets, proteins, nutrients or interfere with their function. Blood disorders covered under the market scope include anemia, bleeding disorders such as hemophilia, and blood cancers such as lymphoma, leukemia, and myeloma among others. Blood Disorder Therapeutics Market is segmented By Product Type, By Application and Geography.

By Product Type

Plasma Derived Factors

Recombinant Factors

Other Products

By Application

Hemoglobin Diosrders

Platelet Based Disorders

Plasma Disorders

Myeloproliferative Disorders

Genetic Hematology Disorders

Blood Cancers

Other Application

Geography

North America	United States
	Canada
	Mexico
Europe	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe
Asia-Pacific	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific
Middle-East and Africa	GCC
	South Africa
	Rest of Middle-East and Africa
South America	Brazil
	Argentina
	Rest of South America

By Product Type	Plasma Derived Factors
	Recombinant Factors
	Other Products
By Application	Hemoglobin Diosrders
	Platelet Based Disorders
	Plasma Disorders
	Myeloproliferative Disorders
	Genetic Hematology Disorders
	Blood Cancers
	Other Application

Geography	North America	United States
		Canada
		Mexico

	Europe	Germany
		United Kingdom
		France
		Italy
		Spain
		Rest of Europe

	Asia-Pacific	China
		Japan
		India
		Australia
		South Korea
		Rest of Asia-Pacific

	Middle-East and Africa	GCC
		South Africa
		Rest of Middle-East and Africa

	South America	Brazil
		Argentina
		Rest of South America

Need A Different Region or Segment?

Customize Now

Key Questions Answered in the Report

What is the current Blood Disorder Therapeutics Market size?

The Blood Disorder Therapeutics Market is projected to register a CAGR of 6.2% during the forecast period (2025-2030)

Who are the key players in Blood Disorder Therapeutics Market?

Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi, Novo Nordisk A/S, CSL Ltd and Pfizer Inc are the major companies operating in the Blood Disorder Therapeutics Market.

Which is the fastest growing region in Blood Disorder Therapeutics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Blood Disorder Therapeutics Market?

In 2025, the North America accounts for the largest market share in Blood Disorder Therapeutics Market.

What years does this Blood Disorder Therapeutics Market cover?

The report covers the Blood Disorder Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Blood Disorder Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Page last updated on: December 2, 2025